Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. May 15, 2026; 18(5): 117085
Published online May 15, 2026. doi: 10.4251/wjgo.v18.i5.117085
Published online May 15, 2026. doi: 10.4251/wjgo.v18.i5.117085
Impact of sintilimab with first-line therapy on tumor marker response in advanced gastric cancer
Hong-Liang Quan, Lin Xia, Yan Hu, Gui-Yuan Wang, Department of Oncology, Hefei BOE Hospital, Hefei 230013, Anhui Province, China
Chao Wang, Department of Oncology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei 238000, Anhui Province, China
Author contributions: Quan HL and Wang C designed the research study and wrote the manuscript; Xia L and Hu Y performed the research and collected the data; Wang GY and Wang C analyzed the data; all authors have read and approved the final manuscript.
Supported by 2024 Hefei BOE Hospital Institutional Research Project, No. YJKT2024008; and Anhui Provincial Higher Education Scientific Research Project (Natural Science Category), No. 2024AH050672.
Institutional review board statement: The research was reviewed and approved by Hefei BOE Hospital.
Clinical trial registration statement: This study has not yet been registered with clinical trials.
Informed consent statement: All participants provided informed consent.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: No other data available.
Corresponding author: Chao Wang, Chief Physician, Department of Oncology, The Fourth Affiliated Hospital of Anhui Medical University, No. 64 Chaohu North Road, Hefei 238000, Anhui Province, China. wangchao10107@163.com
Received: December 2, 2025
Revised: December 29, 2025
Accepted: February 6, 2026
Published online: May 15, 2026
Processing time: 162 Days and 16.8 Hours
Revised: December 29, 2025
Accepted: February 6, 2026
Published online: May 15, 2026
Processing time: 162 Days and 16.8 Hours
Core Tip
Core Tip: This study demonstrated that sintilimab plus S-1 plus oxaliplatin/xeloda plus oxaliplatin regimen therapy significantly enhanced the reduction in tumor markers and improved tumor marker response rates in patients with advanced gastric cancer. The early and profound decrease in these markers showed a significant positive correlation with objective tumor shrinkage, highlighting their potential as valuable dynamic indicators for evaluating the efficacy of this immunochemotherapy combination.